<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545607</url>
  </required_header>
  <id_info>
    <org_study_id>B01-04</org_study_id>
    <nct_id>NCT03545607</nct_id>
  </id_info>
  <brief_title>MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study</brief_title>
  <acronym>MASTERS-2</acronym>
  <official_title>MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athersys, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Athersys, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell
      investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in
      the previous 18-36 hours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of disability by examining the distribution of modified Rankin Scale (mRS) scores [scale range = 0 to 6] evaluated by shift analysis</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects achieving an excellent functional outcome defined by all of the following criteria:</measure>
    <time_frame>365 days</time_frame>
    <description>mRS score = 0 to 1 [scale range 0 to 6]; and NIHSS score = 0 to 1 [scale range 0 to 42]; and Barthel Index score = greater than or equal to 95 [scale range 0 to 100]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects achieving an excellent functional outcome defined by all of the following criteria:</measure>
    <time_frame>90 days</time_frame>
    <description>mRS score = 0 to 1 [scale range 0 to 6]; and NIHSS score = 0 to 1 [scale range 0 to 42]; and Barthel Index score = greater than or equal to 95 [scale range 0 to 100]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with a mRS score of less than or equal to 2 [scale range 0 to 6] demonstrating the ability to function independently</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>MultiStem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2 billion cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MultiStem</intervention_name>
    <description>single intravenous infusion 18-36 hours after stroke</description>
    <arm_group_label>MultiStem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single intravenous infusion 18-36 hours after stroke</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          -  Male or female subjects ≥18 years of age

          -  Clinical diagnosis of ischemic stroke involving cerebral cortex

          -  Occurrence of a moderate to moderately severe stroke with a persistent neurologic
             deficit documented by a NIHSS score of 8 to 20 (inclusive) that does not change by ≥4
             points during the initial screening period

          -  A mRS score of 0 or 1 prior to the onset of symptoms of the current stroke

        Primary Exclusion Criteria:

          -  Presence of a lacunar or a brainstem infarct

          -  Comatose state

          -  Brain hemorrhage

          -  Major neurological event such as stroke or clinically significant head trauma within 6
             months of enrollment into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Mays, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Athersys, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Athersys Clinical Trials Group</last_name>
    <phone>(216) 426-3597</phone>
    <email>masters2@athersys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Athersys Investigational Site 108</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials</last_name>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 103</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials</last_name>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 104</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials</last_name>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 102</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials</last_name>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 107</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials</last_name>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 106</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials</last_name>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 115</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 101</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athersys Clinical Trials</last_name>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athersys Investigational Site 105</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-426-3597</phone>
      <email>masters2@athersys.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, Yavagal DR, Uchino K, Liebeskind DS, Auchus AP, Sen S, Sila CA, Vest JD, Mays RW. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 May;16(5):360-368. doi: 10.1016/S1474-4422(17)30046-7. Epub 2017 Mar 17.</citation>
    <PMID>28320635</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>adult stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

